Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: J Invest Dermatol. 2017 Jun 7;137(10):2187–2196. doi: 10.1016/j.jid.2016.12.033

Figure 1. Dual vemurafenib and selumetinib treatment is insufficient to restrict protein translation in lines with dual BRAF and MEK inhibitor resistance.

Figure 1.

Western blot of parental YUMAC and YURIF, as well as dual-resistant YUMACdr and YURIFdr, shows significant downregulation of new protein translation at low concentrations in YUMAC and YURIF but only at the highest concentrations in YUMACdr and YURIFdr. Erk, extracellular signal-regulated kinase; MEK, MAPK/ERK kinase; p90RSK, p90 subfamily of ribosomal S6 kinase; RPS6, ribosomal protein S6.